{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:11:57Z","timestamp":1793945517590,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,24]],"date-time":"2016-09-24T00:00:00Z","timestamp":1474675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00535-016-1266-1","type":"journal-article","created":{"date-parts":[[2016,9,24]],"date-time":"2016-09-24T01:15:39Z","timestamp":1474679739000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review"],"prefix":"10.1007","volume":"52","author":[{"given":"Laura","family":"Martelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,24]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrgastro.2013.31","volume":"10","author":"L Peyrin-Biroulet","year":"2013","unstructured":"Peyrin-Biroulet L, Fiorino G, Buisson A, et al. First-line therapy in adult Crohn\u2019s disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013;10:345\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1266_CR2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552\u201363.","journal-title":"Arthritis Rheum"},{"key":"1266_CR3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol. 2009;104:760\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1266_CR4","first-page":"531","volume":"13","author":"MT Arias","year":"2015","unstructured":"Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13:531\u20138.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"1266_CR5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946\u201364.","journal-title":"Clin Ther"},{"key":"1266_CR6","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","volume":"65","author":"AA Fasanmade","year":"2009","unstructured":"Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211\u201328.","journal-title":"Eur J Clin Pharmacol"},{"key":"1266_CR7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348:601\u20138.","journal-title":"N Engl J Med"},{"key":"1266_CR8","first-page":"1248","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:1248\u201354.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"1266_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","volume":"59","author":"CH Seow","year":"2010","unstructured":"Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49\u201354.","journal-title":"Gut"},{"key":"1266_CR10","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","volume":"147","author":"OJ Adedokun","year":"2014","unstructured":"Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147:1296\u2013307.","journal-title":"Gastroenterology"},{"key":"1266_CR11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","volume":"63","author":"F Cornillie","year":"2014","unstructured":"Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721\u20137.","journal-title":"Gut"},{"key":"1266_CR12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/apt.13335","volume":"42","author":"S Paul","year":"2015","unstructured":"Paul S, Roblin X, Peyrin-Biroulet L. Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:939\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"1266_CR13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.crohns.2012.03.018","volume":"7","author":"F Baert","year":"2013","unstructured":"Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn\u2019s patients. J Crohns Colitis. 2013;7:154\u201360.","journal-title":"J Crohns Colitis."},{"key":"1266_CR14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320\u20139.","journal-title":"Gastroenterology"},{"key":"1266_CR15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME Valk van der","year":"2014","unstructured":"van der Valk ME, Mangen M-JJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut. 2014;63:72\u20139.","journal-title":"Gut"},{"key":"1266_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/annrheumdis-2013-204101","volume":"74","author":"CLM Krieckaert","year":"2015","unstructured":"Krieckaert CLM, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74:361\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1266_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/BTT.S96982","volume":"10","author":"J Laine","year":"2016","unstructured":"Laine J, Jokiranta TS, Eklund KK, et al. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-\u03b1 blockers. Biol Targets Ther. 2016;10:67\u201373.","journal-title":"Biol Targets Ther"},{"key":"1266_CR18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","volume":"63","author":"C Steenholdt","year":"2014","unstructured":"Steenholdt C, Brynskov J, Thomsen O\u00d8, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919\u201327.","journal-title":"Gut"},{"key":"1266_CR19","first-page":"654","volume":"11","author":"FS Velayos","year":"2013","unstructured":"Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn\u2019s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11:654\u201366.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"1266_CR20","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v3.29229","author":"X Roblin","year":"2015","unstructured":"Roblin X, Attar A, Lamure M, et al. Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn\u2019s disease patients who lose response to infliximab. J Mark Access Health Policy. 2015. doi: 10.3402\/jmahp.v3.29229","journal-title":"J Mark Access Health Policy."},{"key":"1266_CR21","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1007\/s10620-015-3581-4","volume":"60","author":"C Steenholdt","year":"2015","unstructured":"Steenholdt C, Brynskov J, Thomsen O\u00d8, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn\u2019s disease patients failing infliximab. Dig Dis Sci. 2015;60:2762\u201370.","journal-title":"Dig Dis Sci"},{"key":"1266_CR22","unstructured":"Attar A, Duru G, Roblin X, et al. Test-based versus empirical de-escalation strategy of Crohn\u2019s disease patients in remission with infliximab optimized treatment: a discrete model event cost savings study (submitted study waiting for acceptance)."},{"key":"1266_CR23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10729-007-9026-7","volume":"11","author":"B Sobolev","year":"2008","unstructured":"Sobolev B, Harel D, Vasilakis C, et al. Using the statecharts paradigm for simulation of patient flow in surgical care. Health Care Manag Sci. 2008;11:79\u201386.","journal-title":"Health Care Manag Sci."},{"key":"1266_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1478-7547-4-19","volume":"4","author":"A Lay Le","year":"2006","unstructured":"Le Lay A, Despiegel N, Fran\u00e7ois C, et al. Can discrete event simulation be of use in modelling major depression? Cost Eff Resour Alloc CE. 2006;4:19.","journal-title":"Cost Eff Resour Alloc CE."}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1266-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-016-1266-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1266-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:36:24Z","timestamp":1498332984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-016-1266-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,24]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1266-1","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,24]]}}}